Trial of QOL for Cancer Genomics and Advanced Therapeutics among patient and their family members

JRCT ID: jRCT1030200039

Registered date:01/06/2020

Basic Information

• Recruitment status: Recruiting
• Health condition(s) or Problem(s) studied: Malignant solid tumors or Cancer of unknown primary
• Date of first enrollment: 19/05/2020
• Target sample size: 500
• Study type: Observational

Outcome(s)

Primary Outcome

Prevalence of depression
at before comprehensive cancer genome profiling test, at the time of explanation of the result, at three times after the test, at the six months after the test

Secondary Outcome

Anxiety, QOL, Symptom, Satisfaction, Quality of communication, Knowledge of comprehensive cancer genome profiling test, Social support, Medical backgorund, Social background, Medical information
at before comprehensive cancer genome profiling test, at the time of explanation of the result, at three times after the test, at the six months after the test

Key inclusion & exclusion criteria

• Age minimum: Not applicable
• Age maximum: Not applicable
• Gender: Both

Include criteria

Patients
1) Patients at National Cancer Center Hospital
2) Pathologically diagnosed as malignant solid tumor
3) Planned to perform comprehensive cancer genome profiling
4) With written informed consent
Family member of Patients
1) Family member of Patients consented to this trial
2) Family member of Patients who also attend the appointment for result of comprehensive cancer genome profiling
3) Family member of Patients with written informed consent

Exclude criteria

Patients
1) Patients with difficulty writing and reading Japanese
2) Others judged by the investigator to be unsuitable for the study
Family member of Patients
1) Family member of Patients difficulty writing and reading Japanese
2) Family member of Patients who was others judged by the investigator to be unsuitable for the study

Related Information

• Primary Sponsor: Koyama Takafumi